China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

Zhou, M; Chen, XY; Zhang, H; Xia, L; Tong, X; Zou, LM; Hao, RM; Pan, JH; Zhao, X; Chen, DM; Song, YY; Qi, YL; Tang, L; Liu, ZF; Gao, R; Shi, YK; Yang, ZM

Yang, ZM (reprint author), China Natl Med Prod Adm, Ctr Drug Evaluat, Med Review Dept 1, 128 Jianguo Rd, Beijing 100022, Peoples R China.

CANCER COMMUNICATIONS, 2019; 39 ():

Abstract

Background: On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inh......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索